Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program.

Julia Cave Arbanas,Cheryl L Damberg,Mei Leng,Nina Harawa,Catherine A Sarkisian,Bruce E Landon,John N Mafi

JAMA internal medicine（2023）

引用 3|浏览3

暂无评分

摘要

This cross-sectional cost analysis uses data from the 2018 Health and Retirement Study to estimate the potential future Medicare spending and beneficiary costs for lecanemab.

查看译文

关键词

lecanemab,annual spending,ancillary costs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要